Table of ContentsView AllTable of ContentsSymptomsCausesDiagnosisTreatment
Table of ContentsView All
View All
Table of Contents
Symptoms
Causes
Diagnosis
Treatment
Lung adenocarcinoma is a form ofnon-small cell lung cancer (NSCLC), the most common type of lung cancer. NSCLCs account for 80% of lung malignancies and, of these, roughly 50% are adenocarcinomas.Today, adenocarcinoma is the most common form of lung cancer in women, Asians, andpeople under 45, and can even affect non-smokers who have never smoked one cigarette.
While the rate of adenocarcinoma has been decreasing in men and leveling off in women, the numbers continue to rise in young, non-smoking women—and researchers are not entirely sure why.It is largely believed that genetics,secondhand smoke, and exposure to radon in the home are all contributing factors. Unfortunately, research into the possible causes is lacking, likely partly due to the fact that lung cancer is largely considered a “smoker’s disease.”
Why Lung Cancer Is Increasing in Never Smokers
Verywell / JR Bee
Symptoms of Lung Adenocarcinoma
Lung adenocarcinomas usually begin in tissues near the outer portion of the lungs and may be there for a long time before symptoms appear. When they finally appear, the signs are often less obvious than other forms of lung cancer, manifesting with achronic coughandbloody sputumonly in later, more advanced stages of the disease.
Because of this, some of the more generalizedearly symptoms(such as fatigue, subtle shortness of breath, or upper back and chest pain) may be missed or attributed to other causes. As a result, diagnoses are often delayed, particularly among young people and non-smokers who may have never considered cancer a possibility or a threat.
As with all cancers, the cause of lung adenocarcinoma remains largely unknown. Research strongly suggests that genetic, environmental, and lifestyle factors play a part in the onset, risk, and severity of the disease.
Genetics
As one of three subtypes of NSCLC, lung adenocarcinoma is believed to be associated with certain genetic mutations that may predispose a person to the disease.
These include a mutation of theepidermal growth factor receptor (EGFR) gene, which provides the body with instructions on how to make structural proteins and regulates the speed at which that occurs. There are at least 10 known mutations that can affect the gene and cause cells to replicate abnormally and out of control.
EGFR mutations are more commonly associated with less aggressive low- to intermediate-grade adenocarcinomas.
Other mutations associated with lung adenocarcinoma include those affecting theKirsten rat sarcoma (KRAS) gene. Like EGFR, KRAS also regulates cell growth, maturation, and death; mutations are seen in 20% to 40% of lung adenocarcinoma cases.
However, people whose tumors have KRAS mutations typically have a poor prognosis. Even if the cancer responds well to initialchemotherapy, the disease almost invariably returns.
Other mutations may occur spontaneously; scientists are uncertain why.
Health Concerns and Lifestyle
Genetics only play a part in the risk of lung adenocarcinoma. Other factors contribute significantly, not least of which istobacco smoking.
According to the longstanding Nurses' Health Study, people who have smoked for 30 to 40 years are more than twice as likely to develop lung adenocarcinoma than those who never smoked. The risk is further doubled if you smoked for more than 40 years.
Secondhand smokeexposure also increases your risk.
Other factors that put you at risk for lung adenocarcinoma include:
These and other non-smoking-related risk factors account for why 20% of lung cancers occur in people who have never smoked a cigarette in their life.
Lung cancer is often first detected when abnormalities are seen on an X-ray, usually in the form of apoorly defined shadow. While distressing, the finding at least offers the opportunity for early diagnosis.
In as many as 25% of lung cancer cases, achest X-ray will not detect any irregularitiesand may return a perfectly “normal” diagnosis.
If cancer is suspected, other, more sensitive diagnostics may be used, including:
If there are any lingering concerns after a chest X-ray, such further studies should be ordered.
Sputum cytology, in which a sample of coughed up saliva and mucus is evaluated, may also be used, but this is considered less useful in diagnosing early cancer.
Depending on the results, your healthcare provider may want to obtain a sample of lung tissue to confirm the diagnosis. In addition to more invasivelung tissue biopsies, a newer blood test called aliquid biopsymay be able to follow specific genetic abnormalities in lung cancer cells such as EGFR mutations.
Genetic Profiling
One of the more exciting advances in oncology has been the use of genetic testing to profile cancer cells. By doing so, healthcare providers can select treatments able to target those specific genetic variations.
Current guidelines recommend that all persons with advanced lung adenocarcinoma have PD-L1 immunohistochemistry (PD-L1 IHC) conducted. This test profiles one’s cancer and helps predict the potential effectiveness of one of four immunotherapy drugs approved for the treatment of the disease.
That said, PD-L1 testing is far from perfect in predicting who will or will not respond to these drugs. Other tests, such as tumor mutation burden (the number of mutations present in a tumor) may help identify who will most benefit from these newer targeted therapies.
Reviewing your molecular and PD-L1 tests is one of the most important steps when first diagnosed with advanced lung adenocarcinoma.Specific treatments are available not only for those with EGFR mutations but other treatable mutations such as BRAF, ERBB2,ALK rearrangements,ROS1 rearrangements, and others.
Cancer Staging
Once a cancer diagnosis is confirmed, the healthcare provider will stage the disease based on a series of standard tests. The aim of staging is to determine how advanced the lung cancer is and to what extent it has spread (metastasized).
Staging helps direct treatment in a more appropriate manner so that a malignancy is neither undertreated (affecting outcomes) nor overtreated (causing unnecessary side effects).
Beyond that, there are four stages that are defined as follows. These terms will be used when discussing treatment options.
Depending on the stage of the disease, treatment may include one therapy or a combination.
Targeted therapies have a different spectrum of side effects that are, in general, less severe than the side effects of chemotherapy.Clinical trialsare in the process of identifying more common mutations that can be targeted with medication. This area of treatment is still in its infancy and rapidly evolving.
Clinical trials of targeted and other therapies provide hope to those in whom approved treatments have either failed or cause severe side effects. The NCI recommends that people with lung cancer consider taking part in a clinical trial.
In the past, the likelihood that a clinical trial would make a difference for a person with cancer was small, but this is changing rapidly as specific targets in the pathway of cancer cell division are identified. Many people with stage 4 lung cancer are only alive because of their participation in a clinical trial.
Finally, many healthcare providers recommend getting asecond opinionfrom another specialist or one of theNational Cancer Institute (NCI)-designated treatment centersactively involved in lung cancer research. Doing so can help ensure you get the most up-to-date treatment information and are better able to make an informed choice.
A Word From Verywell
Because the early symptoms of lung cancer are often difficult to spot, the average five-yearsurvival rateis only around 18%. For those diagnosed in the early stages, the outlook is far more promising.
What this highlights is the need for greater awareness about the nonspecific or atypical symptoms of lung cancer. On their own, the symptoms may be easy to miss. Together, they may raise a red flag that can lead to early diagnosis and earlier, more effective treatment.
10 Best Cancer Hospitals in the U.S.
21 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
Cancer Support Community.Non-small cell lung cancer. 2019.
Smolle E, Pichler M.Non-smoking-associated lung cancer: A distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition.Cancers (Basel).2019;11(2):204. doi:10.3390/cancers11020204
American Cancer Society.Facts & figures 2018: Rate of deaths from cancer continues decline.
American Cancer Society.What causes lung cancer?.
American Cancer Society.Signs and symptoms of lung cancer.
Lin CY, Wu YM, Hsieh MH, et al.Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma.PLoS ONE. 2017;12(10):e0186567. doi:10.1371/journal.pone.0186567
Kanwal M, Ding XJ, Cao Y.Familial risk for lung cancer.Oncol Lett.2017;13(2):535-42. doi:10.3892/ol.2016.5518
National Cancer Institute.‘Unexpected’ vulnerability creates treatment opportunity in aggressive type of lung cancer.
Chang ET, Lau EC, Moolgavkar SH.Smoking, air pollution, and lung cancer risk in the Nurses' Health Study cohort: time-dependent confounding and effect modification.Crit Rev Toxicol. 2020;50(3):189-200. doi:10.1080/10408444.2020.1727410
Dela Cruz CS, Tanoue LT, Matthay RA.Lung cancer: epidemiology, etiology, and prevention.Clin Chest Med.2011;32(4):605-44. doi:10.1016/j.ccm.2011.09.001
American Cancer Society.Lung cancer risks for non-smokers.
Del Ciello A, Franchi P, Contegiacomo A, Cicchetti G, Bonomo L, Larici AR.Missed lung cancer: when, where, and why?.Diagn Interv Radiol. 2017;23(2):118-126. doi:10.5152/dir.2016.16187
American Cancer Society.Tests for lung cancer.
Kim H, Chung JH.PD-L1 testing in non-small cell lung cancer: Past, present, and future.J Pathol Transl Med.2019;53(4):199-206. doi:10.4132/jptm.2019.04.24
American Cancer Society.Immune checkpoint inhibitors and their side effects.
American Cancer Society.Non-small cell lung cancer stages.
American Cancer Society.Radiation therapy for non-small cell lung cancer.
American Cancer Society.Immunotherapy for non-small cell lung cancer.
National Cancer Institute.Treatment clinical trials for non-small cell lung cancer. 2019.
American Lung Association.Lung cancer fact sheet.
Meet Our Medical Expert Board
Share Feedback
Was this page helpful?Thanks for your feedback!What is your feedback?OtherHelpfulReport an ErrorSubmit
Was this page helpful?
Thanks for your feedback!
What is your feedback?OtherHelpfulReport an ErrorSubmit
What is your feedback?
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.Cookies SettingsAccept All Cookies
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookies SettingsAccept All Cookies
